

Docket No.

257550US0PCT

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Mario PINZA, et al.

SERIAL NO:

10/507,025

GAU:

FILED:

September 8, 2004

**EXAMINER:** 

FOR:

USE OF AN L-ASCORBIC ACID SALT TO PREPARE A PHARMACEUTICAL COMPOSITION, FOR

OPHTHALMIC TOPICAL USE, CAPABLE OF IMPROVING THE LEVEL OF L-ASCORBIC ACID IN THE EYE

# **INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

### REFERENCES

The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

### **RELATED CASES**

Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

# **CERTIFICATION**

☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

□ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

# DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

Docket No.

257550US0PCT

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Mario PINZA, et al.

SERIAL NO:

): 10/507,025

GAU:

FILED:

September 8, 2004

**EXAMINER:** 

FOR:

USE OF AN L-ASCORBIC ACID SALT TO PREPARE A PHARMACEUTICAL COMPOSITION, FOR

OPHTHALMIC TOPICAL USE, CAPABLE OF IMPROVING THE LEVEL OF L-ASCORBIC ACID IN THE EYE

# INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

#### REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

#### **RELATED CASES**

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

# CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

# DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

Form PTO 1449		U.S. DEPARTMENT		ATTY DOCKET NO.		SERIAL NO.			
(Modified)		PATENT AND TRADEMARK OFFICE		257550US0PCT	10/507,025				
				APPLICANT					
LIST OF REFERENCES CITED BY APPLICANT				Mario PINZA, et al.					
				FILING DATE		GROUP			
				September 8, 2004					
				U.S. PATENT DOCUMENTS				•	
EXAMINER		DOCUMENT				SUB	FILI	NG DATE	
INITIAL		NUMBER	DATE	NAME	CLASS	CLASS			
	AA	4 620 979	11/04/86	SCHACHAR, Ronald A.					
	AB	5 817 630	10/06/98	BOTTONI, Don J. et al.					
	AC	5 523 316	06/04/96	GAN, Owen et al.					
	AD	4 886 815	12/12/89	SCHACHAR, Ronald A.					
	AE								
	AF							-	
	AG								
	AH								
	Al								
	AJ								
	AK								
	AL								
	АМ						-		
	AN					_			
	1	<u>.                                    </u>	FO	REIGN PATENT DOCUMENTS	<b>.</b>		<u> </u>		
	Γ		1						
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO			
	AO	02 01954	01/10/02	wo				NO	
	ΑP	0 781 547	07/02/97	EP				NO	
	AQ	197 29 879	01/14/99	DE (equivalent of US 6605295)	-			NO	
	AR	31 33 003	03/10/83	DE (with English abstract)				NO	
	AS	58 021614	02/08/83	JP (English abstract only)				NO	
	AT								
	AU					<u> </u>			
	AV								
	I,	OTHER RE	FERENCES (	Including Author, Title, Date, Pertinent	t Pages. e	tc.)		• • • • • • • • • • • • • • • • • • • •	
	·		`		_		nology ch:	anter 4 20 2	
	AW	ARSHINOFF, Steve A. et al. "Lens Surgery: The Pharmacotherapy of Cataract Surgery", Ophthalmology, chapter 4.20.2, published by Mosby International Ltd. 1999							
	AX	BRUBAKER, Richard F. "Ascorbic Acid Content of Human Corneal Epithelium", Investigative Ophthalmology & Visual Science, vol. 41, no. 7, pages 1681-1683							
	AY	2000 Edited by LENTNER, C. "Physical Chemistry Composition of Blood Hematology Somatometric Data", Geigy Scientific Tables, vol. 3, 8 <sup>th</sup> edition, page 132							
	1985								
	AZ				Add	Additional References sheet(s) attached			
Examiner				Date Considered					
*Examiner: Ir conformance	nitial if r	reference is considered, ot considered. Include co	whether or no	t citation is in conformance with MPEP 60 n with next communication to applicant.	09; Draw li	ne through	citation if	not in	
L			_ · ·						

U.S. PCT Application Serial No.: 10/507,025 Docket No.: <u>257550US0PCT</u>

# STATEMENT OF RELEVANCY

Report. C	Copies of th	nese references are be	have been cited in the In hing submitted herewith or hal Searching Authority.	
		have been cite erences is being subm	ed in the corresponding itted herewith.	Search Report.
-		AW-AY are discussubmitted here with.	sed in the specification. A	copy of these
		are additional peing submitted herew	l prior art known to Applivith.	cant. A copy of